Furthermore, high SEC61G expression in breast cancer patients with tumor, nodes, and metastases (TNM) stage I–II or TNM III–IV also exhibited markedly lower rates of overall survival and disease-free survival compared with patients with low SEC61G expression (Fig. 1E, F). This evidence concerns the gene SEC61G and neoplasm.